Currently, two DNA methylation biomarkers for colorectal cancer (CRC) have been approved by the FDA: SEPT9, utilized in blood screening tests, and a combination of NDRG4 and BMP3 for stool tests [7]. This evidence concerns the gene BMP3 and colorectal carcinoma.